Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: A prospective study in patients with hematological malignancies

Supportive Care in Cancer

Volumn 13, Issue 12, 2005, Pages 987-992

  Girmenia, Corrado ^a   Cimino, Giuseppe ^a   Di Cristofano, Francesca ^a   Micozzi, Alessandra ^a   Gentile, Giuseppe ^a   Martino, Pietro ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Amphotericin B deoxycholate; Empirical therapy; Hydration; Nephrotoxicity; Sodium

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CREATININE; ELECTROLYTE; MAGNESIUM; PHOSPHORUS; POTASSIUM; SODIUM;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; BODY SURFACE; CANDIDIASIS; CHILL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIURESIS; DOSE RESPONSE; DRUG EFFECT; DYSPNEA; ELECTROLYTE BLOOD LEVEL; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; HYDRATION; KIDNEY FAILURE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RIGOR; SCHOOL CHILD; SODIUM LOAD; STATISTICAL SIGNIFICANCE; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; CHILD; DEHYDRATION; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; KIDNEY; MALE; MIDDLE AGED; POTASSIUM DEFICIENCY; PROSPECTIVE STUDIES; WATER-ELECTROLYTE BALANCE;

EID: 27744436980     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-005-0783-x     Document Type: Article

References (31)

1. Bates DW, Su L, Yu T, Chertow GM, Seger DL, Gomes DRJ, Dasbach EJ, Platt R (2002) Mortality and cost of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686-693
2. Branch RA, Jackson EK, Jacqz E, Stein R, Ray WA, Ohnhaus EE, Meusers P, Heidemann H (1987) Amphotericin B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr 65:500-506
3. Branch RA (1988) Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation. Arch Intern Med 148:2389-2394
4. Butler WT, Bennett JE, Ailing DW, Wertlake PT, Utz JR, Hill GJ (1964) Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 61:175-187
5. Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, Arndt CA, Schuster M, Seibel N, Yeldandi V, Tong KB (2000) Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 18:2476-2483
6. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
7. Feely J, Heidemann H, Gerkens J, Roberts LJ, Branch RA (1981) Sodium depletion enhances nephrotoxicity of amphotericin B. Lancet 1:1422-1423
8. Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL (1989) Risk factors for amphotericin B associated nephrotoxicity. Am J Med 87:547-552
9. Furrer K, Schaffner A, Vavricka SR, Halter J, Imbof A, Schanz U (2002) Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogeneic stem cell transplantation. Swiss Med Wkly 132:316-320
10. Gallis HA, Drew RH, Pickard WW (1990) Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12:308-329
11. Girmenia C, Gentile G, Micozzi A, Martino P (2001) Nephrotoxicity of amphotericin B desoxycholate. Clin Infect Dis 33:915-916
12. Girmenia C, Cimino G, Micozzi A, Gentile G, Martino P (2002) Risk factors for nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 113:351
13. Harbarth S, Burke JP, Lloyd JF, Evans S, Pestotnik SL, Samore MH (2002) Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 35:e120-e127
14. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH (2001) The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 111:528-534
15. Heidemann HAT, Gerkens JF, Spickard WA, Jackson EK, Branch RA (1983) Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 75:476-481
16. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751
17. Imhof A, Waler RB, Schaffner A (2003) Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 36:943-951
18. Johnson JR (2004) Reduction of nephrotoxicity associated with amphotericin B deoxycholate. Clin Infect Dis 38:303
19. Luber AD, Maa L, Lam M, Guglielmo BJ (1999) Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 43:267-271
20. Mayer J, Doubek M, Vorlicek J (1999) Must we really fear toxicity of conventional amphotericin B in oncological patients? Support Care Cancer 7:51-55
21. Mayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M (2002) Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis 186:379-388
22. Ohnishi A, Ohnishi T, Stevenhead W, Robinson RD, Glick A, O'Day DM, Sabra R, Jackson EK, Branch RA (1989) Sodium status influences chronic amphotericin B nephrotoxicity in rats. Antimicrob Agents Chemother 33:1222-1227
23. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new "gold standard". Clin Infect Dis 37:415-425
24. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38:161-189
25. Pathak A, Pien FD, Carvalho L (1998) Amphotericin B use in a community hospital, with special emphasis on side effects. Clin Infect Dis 26:334-338
26. Sabra R, Branch RA (1990) Amphotericin B nephrotoxicity. Drug Saf 5:94-108
27. Spellberg B, Witt MD, Beck CK (2004) Amphotericin B: is a lipid-formulation gold standard feasible? Clin Infect Dis 38:304-305
28. Stein RS, Alexander JA (1989) Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am Med Sci 298:299-304
29. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey G (2000) Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 30:696-709
30. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New Engl J Med 340:764-771
31. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, Bowden R, Anaissie E, Hiemenz J, Lister J (1999) Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29:1402-1407